[HTML][HTML] Enhanced efficacy of PEGylated liposomal cisplatin: In vitro and in vivo evaluation
M Ghaferi, MJ Asadollahzadeh, A Akbarzadeh… - International journal of …, 2020 - mdpi.com
This study aims to evaluate the potency of cisplatin (Cispt)-loaded liposome (LCispt) and
PEGylated liposome (PLCispt) as therapeutic nanoformulations in the treatment of bladder …
PEGylated liposome (PLCispt) as therapeutic nanoformulations in the treatment of bladder …
In vivo glioblastoma therapy using targeted liposomal cisplatin
MS Ashrafzadeh, A Akbarzadeh… - International Journal …, 2020 - Taylor & Francis
Background: Drug delivery systems have demonstrated promising results to cross blood–
brain barrier (BBB) and deliver the loaded therapeutics to the brain tumor. This study aims to …
brain barrier (BBB) and deliver the loaded therapeutics to the brain tumor. This study aims to …
Encapsulation of cisplatin in long-circulating and pH-sensitive liposomes improves its antitumor effect and reduces acute toxicity
EA Leite, CM Souza, ÁD Carvalho-Júnior… - International Journal …, 2012 - Taylor & Francis
Cisplatin (CDDP) is one of the most effective and potent anticancer drugs used as first-line
chemotherapy against several solid tumors. However, the severe side effects and its …
chemotherapy against several solid tumors. However, the severe side effects and its …
Acute toxicity study of cisplatin loaded long-circulating and pH-sensitive liposomes administered in mice
EA Leite, AMQ Lana… - Journal of …, 2012 - ingentaconnect.com
Cisplatin (CDDP) is a very active and cytotoxic agent but causes severe side effects, namely
nephrotoxicity, which limits the therapy. The present study aimed to evaluate the acute …
nephrotoxicity, which limits the therapy. The present study aimed to evaluate the acute …
Caprylate-conjugated cisplatin for the development of novel liposomal formulation
Cisplatin, first (platinum) compound to be evolved as an anticancer agent, has found its
important place in cancer chemotherapy. However, the dose-dependent toxicities of …
important place in cancer chemotherapy. However, the dose-dependent toxicities of …
Preparation, characterization, and cytotoxic effects of liposomal nanoparticles containing cisplatin: an in vitro study
D Poy, A Akbarzadeh… - Chemical Biology & …, 2016 - Wiley Online Library
Cisplatin is a chemotherapeutic agent used for treating various malignancies. The study
aimed to prepare pegylated liposomal cisplatin and evaluate its efficacy against human …
aimed to prepare pegylated liposomal cisplatin and evaluate its efficacy against human …
Optimizing the therapeutic efficacy of cisplatin PEGylated liposomes via incorporation of different DPPG ratios: In vitro and in vivo studies
E Marzban, SH Alavizadeh, M Ghiadi… - Colloids and surfaces B …, 2015 - Elsevier
The anionic lipid DPPG is known to enhance the cellular uptake of liposomes by forming
phase boundaries of high fusogenic potentials in vesicular membranes. The focus of this …
phase boundaries of high fusogenic potentials in vesicular membranes. The focus of this …
Estrone-conjugated PEGylated liposome Co-loaded paclitaxel and carboplatin improve anti-tumor efficacy in ovarian cancer and reduce acute toxicity of chemo-drugs
H Tang, Y Xie, M Zhu, J Jia, R Liu, Y Shen… - International Journal …, 2022 - Taylor & Francis
Purpose Ovarian cancer is the most lethal gynecologic malignancy. The combination of
paclitaxel (PTX) and carboplatin (CBP) is the first-line remedy for clinical ovarian cancer …
paclitaxel (PTX) and carboplatin (CBP) is the first-line remedy for clinical ovarian cancer …
Preparation, characterization and cytotoxic effects of pegylated nanoliposomal containing carboplatin on ovarian cancer cell lines
M Ebrahimifar, A Nili-Ahmadabadi… - Indian Journal of Clinical …, 2017 - Springer
Carboplatin is a chemotherapeutic agent used against various malignancies such as
ovarian carcinoma. The aim of this study is to improve the therapeutic efficacy of carboplatin …
ovarian carcinoma. The aim of this study is to improve the therapeutic efficacy of carboplatin …
Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin
Lipid-polymer hybrid nanoparticles (LPHNP) are delivery systems for controlled drug
delivery at tumor sites. The superior biocompatible properties of lipids and structural …
delivery at tumor sites. The superior biocompatible properties of lipids and structural …